Zacks Analyst Blog Highlights: Cemex S.A. de C.V., Baxter International Inc., Web.com, Gilead Sciences, Inc. and Pfizer Inc.

CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cemex S.A. de C.V. (NYSE: CX), Baxter International Inc. (NYSE: BAX), Web.com (Nasdaq: WWWW), Gilead Sciences, Inc. (Nasdaq: GILD) and Pfizer Inc. (NYSE: PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Monday’s Analyst Blog:

CEMEX Weak Results Continue

CEMEX (NYSE: CX) is a leading global producer of cement and ready-mix products, with operations concentrated in major cement markets of four continents. CEMEX serves clients ranging from individual homebuilders to large industrial contractors.

We are keeping our Sell rating on CEMEX. The company posted weak results in the third quarter of 2008 together with a 74% year-over-year decline in net income. The continued weak cement volumes in Spain and U.S. are problematic.

Baxter Outlook: Safe and Bullish

Baxter International (NYSE: BAX) is a global medical products and services company with expertise in medical devices, pharmaceuticals and biotechnology. The company operates through three main lines of business: BioScience, Medication Delivery and Renal.

We believe these markets will remain relatively insulated from the current economic turmoil, providing investors good quality returns on a risk-adjusted basis. Baxter's strong market position is demonstrated in its recent quarterly performance that exceeded estimates and led the management to increase fiscal 2008 EPS guidance for the second quarter in a row.

Web.com Attractive Long-Term

Web.com (Nasdaq: WWWW) is a leading provider of Web services for small and medium businesses (SMBs). The company uses a factory approach that it can leverage over thousands of customers.

We believe the company is feeling pressure from a slowing consumer market, which many of its customers cater to. However, the long-term still looks bright.

Gilead Offers Opportunities

Foster City, CA, based Gilead Sciences, Inc. (Nasdaq: GILD) is perhaps the world’s premier play on HIV/AIDS therapy. Gilead’s third quarter financial results were solid -- nothing new -- for the company, as management has posted upside surprise after upside surprise throughout the past several years. EPS of $0.55 in the quarter was $0.02 above our forecasts based on strong product sales and lower-than-expected SG&A [selling, general and administrative] costs.

The pipeline is also progressing nicely. Letairis should become the best-in-class ETRA for PAH, and given the lack of drug-drug interactions seen in the phase III trials, it should be used first-line with Pfizer’s (NYSE: PFE) Revatio. We are pleased with the Letairis launch so far and expect a meaningful ramp in sales over the next few quarters.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.